Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
NCT ID: NCT03301350 Phase: PHASE2 Status: COMPLETED Enrollment: 29 Completion: 2022-02-07
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide, Pegfilgrastim, Filgrastim
Summary
This is a phase II single-arm, open-label, prospective study to evaluate the efficacy of the low dose weekly Carboplatin/Paclitaxel followed by dose-dense Doxorubicin/Cyclophosphamide in subjects with triple-negative breast cancer in neoadjuvant settings.
Primary Outcome
Number and Percentage of Participants With Pathologic Complete Response (pCR) Rate